Stocks

JV for malaria drug may lift Ipca Laboratories

| Updated on December 20, 2019 Published on December 21, 2019

Ipca Laboratories on Friday said it has entered into an agreement with Medicines for Malaria Venture to jointly develop a novel antimalarial co-formulation Atoguanil, which contains the active pharmaceutical ingredients atovaquone and proguanil.

“Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries,” it added. Shareholders will closely monitor the developments.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on December 21, 2019
This article is closed for comments.
Please Email the Editor